thrombin receptor peptide sfllrnp has been researched along with beraprost in 1 studies
| Studies (thrombin receptor peptide sfllrnp) | Trials (thrombin receptor peptide sfllrnp) | Recent Studies (post-2010) (thrombin receptor peptide sfllrnp) | Studies (beraprost) | Trials (beraprost) | Recent Studies (post-2010) (beraprost) |
|---|---|---|---|---|---|
| 92 | 10 | 29 | 407 | 61 | 105 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Matsushita, T; Miyamoto, M; Ohno, M; Ohtake, A; Yamada, N | 1 |
1 other study(ies) available for thrombin receptor peptide sfllrnp and beraprost
| Article | Year |
|---|---|
TRA-418, a thromboxane A2 receptor antagonist and prostacyclin receptor agonist, inhibits platelet-leukocyte interaction in human whole blood.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Blood Platelets; Bridged Bicyclo Compounds, Heterocyclic; Cell Communication; Cell Separation; Cells, Cultured; Epinephrine; Epoprostenol; Fatty Acids, Unsaturated; Flow Cytometry; Humans; Hydrazines; Leukocytes; Oxazines; Peptide Fragments; Platelet Activation; Receptors, Epoprostenol; Receptors, Thromboxane A2, Prostaglandin H2; Thrombosis | 2010 |